medical decision support medical decision support
Sign In

Predictors of Dupont-Lucas et al for Response of a Pediatric Patient with Perianal Crohn's Disease to Infliximab Therapy

Description

Dupont-Lucas et al identified predictors of response to infliximab therapy by pediatric patients with perianal Crohn's disease. These can help to identify a patient who may benefit from therapy. The authors are from multiple hospitals in France in the GETAID (Grupe d'Etude therapeutique des Affections Inflammatoires du Tube Digestif) pediatrique.


 

Patient selection: pediatric perianal Crohn's disease

 

Predictors of response at 1 year:

(1) low Harvey-Bradshaw index (< 5)

(2) no or 1 fistula

 

Predictors of relapse after initial response:

(1) duration of Crohn's disease less than 10 months (longer duration protective)

(2) 2 or more fistulae

(3) surgical drainage in the month prior to starting infliximab

 

Combined therapy with an immunomodular was nonpredictive of 1-year response or time of relapse.

 


To read more or access our algorithms and calculators, please log in or register.

Specialty